Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AGIO Stock Forecast 2026-2027
$32.92
Current Price
$1.93B
Market Cap
Buy 6
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to AGIO Price Targets
+97.4%
To High Target of $65.00
+26.1%
To Median Target of $41.50
-14.9%
To Low Target of $28.00
AGIO Price Momentum
-6.5%
1 Week Change
+16.5%
1 Month Change
+30.1%
1 Year Change
+20.9%
Year-to-Date Change
-28.4%
From 52W High of $46.00
+48.0%
From 52W Low of $22.24
📊 TOP ANALYST CALLS
Did AGIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Agios is one of their latest high-conviction picks.
Latest AGIO Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, AGIO has a bullish consensus with a median price target of $41.50 (ranging from $28.00 to $65.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $32.92, the median forecast implies a 26.1% upside. This outlook is supported by 6 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 97.4% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 14.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AGIO Analyst Ratings
6
Buy
3
Hold
0
Sell
AGIO Price Target Range
Low
$28.00
Average
$41.50
High
$65.00
Current: $32.92
Latest AGIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AGIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 6, 2026 | JP Morgan | Tessa Romero | Neutral | Maintains | $36.00 |
| Apr 1, 2026 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $32.00 |
| Mar 5, 2026 | Citigroup | Samantha Semenkow | Buy | Maintains | $46.00 |
| Feb 12, 2026 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $65.00 |
| Jan 6, 2026 | JP Morgan | Tessa Romero | Neutral | Maintains | $25.00 |
| Dec 26, 2025 | Leerink Partners | Andrew Berens | Outperform | Maintains | $40.00 |
| Dec 24, 2025 | B of A Securities | Greg Harrison | Buy | Maintains | $34.00 |
| Dec 24, 2025 | Truist Securities | Gregory Renza | Buy | Maintains | $38.00 |
| Dec 24, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $62.00 |
| Nov 26, 2025 | Citigroup | Samantha Semenkow | Buy | Initiates | $38.00 |
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Initiates | $32.00 |
| Nov 21, 2025 | JP Morgan | Tessa Romero | Neutral | Maintains | $20.00 |
| Nov 20, 2025 | Leerink Partners | Andrew Berens | Outperform | Upgrade | $34.00 |
| Nov 20, 2025 | RBC Capital | Luca Issi | Sector Perform | Downgrade | $28.00 |
| Nov 20, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $48.00 |
| Nov 20, 2025 | B of A Securities | Greg Harrison | Buy | Maintains | $32.00 |
| Nov 20, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $25.00 |
| Sep 4, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $56.00 |
| Jul 28, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $65.00 |
| Jul 22, 2025 | B of A Securities | Greg Harrison | Buy | Maintains | $51.00 |
Agios Pharmaceuticals Inc. (AGIO) Competitors
The following stocks are similar to Agios based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Agios Pharmaceuticals Inc. (AGIO) Financial Data
Agios Pharmaceuticals Inc. has a market capitalization of $1.93B with a P/E ratio of 3.8x. The company generates $54.03M in trailing twelve-month revenue with a 88.3% profit margin.
Revenue growth is +86.1% quarter-over-quarter, while maintaining an operating margin of -608.9% and return on equity of -30.2%.
Valuation Metrics
Market Cap
$1.93B
Enterprise Value
$1.22B
P/E Ratio
3.8x
PEG Ratio
-6.9x
Price/Sales
37.7x
Growth & Margins
Revenue Growth (YoY)
+86.1%
Gross Margin
+90.6%
Operating Margin
-608.9%
Net Margin
+88.3%
EPS Growth
+86.1%
Financial Health
Cash/Price Ratio
+44.3%
Current Ratio
11.5x
Debt/Equity
3.4x
ROE
-30.2%
ROA
-19.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Agios Pharmaceuticals Inc. (AGIO) Business Model
About Agios Pharmaceuticals Inc.
What They Do
Develops medicines for rare diseases and hematology.
Business Model
Agios Pharmaceuticals generates revenue by developing and commercializing small-molecule therapies aimed at treating rare diseases, particularly in the field of hematology. Their lead product, Pyrukynd, is designed to address unmet medical needs in hemolytic anemias, and the company continues to expand its pipeline with additional candidates targeting other blood-related conditions.
Additional Information
Founded in 2007 and based in Cambridge, Massachusetts, Agios Pharmaceuticals focuses on leveraging its expertise in cellular metabolism to innovate therapies that can significantly impact the treatment landscape for patients with genetically defined rare diseases. The company's commitment to advancing these specialized treatments highlights its role in addressing critical medical gaps.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
539
CEO
Mr. Brian M. Goff M.B.A.
Country
United States
IPO Year
2013
Website
www.agios.comAgios Pharmaceuticals Inc. (AGIO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
Apr 01, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Agios Pharmaceuticals will host a conference call and live webcast on April 29, 2026, at 8:00 a.m. ET, focusing on its innovative medicines for rare diseases.
Why It Matters
Agios Pharmaceuticals is hosting a conference call, likely to discuss key developments. Such events can influence stock prices based on new insights or guidance shared with investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky has launched an investigation into Agios Pharmaceuticals (NASDAQ: AGIO) for potential federal securities law violations following the Phase 3 trial results of Mitapivat.
Why It Matters
The investigation into Agios Pharmaceuticals for potential securities law violations could signal financial instability or regulatory issues, impacting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Agios Pharmaceuticals (AGIO) shares rose on high trading volume, with recent earnings estimate revisions indicating potential for future growth.
Why It Matters
Agios Pharmaceuticals' rising share price and increased trading volume indicate growing investor confidence, while positive earnings estimate revisions suggest potential future growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Agios Pharmaceuticals shares rose 14% following positive regulatory feedback, advancing towards accelerated FDA approval for mitapivat in treating sickle cell disease.
Why It Matters
Agios Pharmaceuticals' 14% jump indicates strong investor confidence in potential revenue growth from accelerated FDA approval, signaling a positive outlook for the company's future.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
On March 5, 2026, Krishnan sold 2,959 shares for ~$82,000 at ~$27.80 each, reducing his holdings by 36.5% from 8,100 to 5,141 shares.
Why It Matters
The significant sale of 36.5% of Krishnan's holdings may signal reduced confidence in the company's prospects, potentially impacting stock performance and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Agios Pharmaceuticals' mitapivat shows strong potential for treating sickle cell disease. The FDA has permitted an abbreviated trial to confirm its efficacy before approval.
Why It Matters
Agios Pharmaceuticals' expedited FDA trial for mitapivat boosts its potential market value, signaling confidence in the drug's efficacy for sickle cell disease, which may attract investor interest.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About AGIO Stock
What is Agios Pharmaceuticals Inc.'s (AGIO) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Agios Pharmaceuticals Inc. (AGIO) has a median price target of $41.50. The highest price target is $65.00 and the lowest is $28.00.
Is AGIO stock a good investment in 2026?
According to current analyst ratings, AGIO has 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $32.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AGIO stock?
Wall Street analysts predict AGIO stock could reach $41.50 in the next 12 months. This represents a 26.1% increase from the current price of $32.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Agios Pharmaceuticals Inc.'s business model?
Agios Pharmaceuticals generates revenue by developing and commercializing small-molecule therapies aimed at treating rare diseases, particularly in the field of hematology. Their lead product, Pyrukynd, is designed to address unmet medical needs in hemolytic anemias, and the company continues to expand its pipeline with additional candidates targeting other blood-related conditions.
What is the highest forecasted price for AGIO Agios Pharmaceuticals Inc.?
The highest price target for AGIO is $65.00 from Emily Bodnar at HC Wainwright & Co., which represents a 97.4% increase from the current price of $32.92.
What is the lowest forecasted price for AGIO Agios Pharmaceuticals Inc.?
The lowest price target for AGIO is $28.00 from Luca Issi at RBC Capital, which represents a -14.9% decrease from the current price of $32.92.
What is the overall AGIO consensus from analysts for Agios Pharmaceuticals Inc.?
The overall analyst consensus for AGIO is bullish. Out of 17 Wall Street analysts, 6 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $41.50.
How accurate are AGIO stock price projections?
Stock price projections, including those for Agios Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 3:18 AM UTC